Advertisement

International Journal of Hematology

, Volume 110, Issue 6, pp 743–750 | Cite as

Supportive care for hemostatic complications associated with pediatric leukemia: a national survey in Japan

  • Shinya OsoneEmail author
  • Keitaro Fukushima
  • Michihiro Yano
  • Mariko Kakazu
  • Hirozumi Sano
  • Yoko Kato
  • Yuichi Shinkoda
  • Kunihiro Shinoda
  • Naoko Mori
  • Souichi Adachi
Original Article
  • 84 Downloads

Abstract

Optimal supportive care for disseminated intravascular coagulation (DIC) and hemostatic complications by asparaginase is indispensable for the successful treatment of pediatric leukemia. However, the situation regarding this type of care in Japan is unclear. We conducted a questionnaire-based survey at 155 institutions treating childhood leukemia in Japan. The questionnaire asked about the supportive care provided by each institution to acute leukemia patients with DIC and asparaginase-induced hemostatic alterations. Ninety-eight institutions responded. The most common diagnostic criteria for DIC were those established by the Japanese Ministry of Health and Welfare. Regardless of the etiology underlying DIC, recombinant human thrombomodulin and synthetic protease inhibitors were used as anticoagulation therapy by around 70% and 40% of institutions, respectively. Additionally, 92%, 93%, and 73% of institutions measured plasma antithrombin, fibrinogen, and D-dimer/fibrin degradation products, respectively, more than twice per week during induction therapy for acute lymphoblastic leukemia. Survey responses indicate that 95% and 24% of the institutions used antithrombin replacement and fresh-frozen plasma, respectively. Supportive care for DIC and/or asparaginase-induced hemostatic alterations at Japanese pediatric centers was intensive and differs markedly from protocols in other countries. The efficacy of supportive care should be evaluated prospectively in the setting of pediatric leukemia.

Keywords

Leukemia Children Disseminated intravascular coagulation Asparaginase-induced thrombosis Supportive care 

Abbreviations

ALL

Acute lymphoblastic leukemia

DIC

Disseminated intravascular coagulation

JPLSG

The Japanese Pediatric Leukemia/Lymphoma Study Group

FDP

Fibrin degradation products

FFP

Fresh-frozen plasma

JMHW

The Japanese Ministry of Health and Welfare

JSTH

The Japanese Society on Thrombosis and Hemostasis

JAAM

The Japanese Association for Acute Medicine

ISTH

The International Society on Thrombosis and Hemostasis

rhTM

Recombinant human thrombomodulin

BFM

Berlin–Frankfurt–Münster

Notes

Acknowledgements

We thank all participants listed in Supplemental material 2 for answering the questions.

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to declare.

Supplementary material

12185_2019_2740_MOESM1_ESM.docx (27 kb)
Supplementary file1 (DOCX 26 kb)
12185_2019_2740_MOESM2_ESM.docx (17 kb)
Supplementary file2 (DOCX 16 kb)

References

  1. 1.
    Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care. 2014;2:15.CrossRefGoogle Scholar
  2. 2.
    De Stefano V, Za T, Ciminello A, Betti S, Rossi E. Haemostatic alterations induced by treatment with asparaginases and clinical consequences. Thromb Haemost. 2015;113:247–61.CrossRefGoogle Scholar
  3. 3.
    Biss TT, Payne JH, Hough RE, Grainger JD, Macartney C, Sibson KR, et al. Strategies to prevent and manage thrombotic complications of acute lymphoblastic leukemia in children and young people vary between centers in the United Kingdom. J Pediatr Hematol Oncol. 2016;38:221–6.CrossRefGoogle Scholar
  4. 4.
    Kobayashi N, Maekawa T, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the research committee on DIC in Japan. Bibl Haematol. 1983;49:265–75.Google Scholar
  5. 5.
    Asakura H, Takahashi H, Uchiyama T, Eguchi Y, Okamoto K, Kawasugi K, et al. Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2016;14:42.CrossRefGoogle Scholar
  6. 6.
    Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34:625–31.CrossRefGoogle Scholar
  7. 7.
    Taylor FB, Toh C-H, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–30.CrossRefGoogle Scholar
  8. 8.
    Wada H, Wakita Y, Nakase T, Shimura M, Hiroyama K, Nagaya S, et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group. Thromb Haemost. 1995;74:848–52.CrossRefGoogle Scholar
  9. 9.
    Wada H, Gabazza EC, Asakura H, Koike K, Okamoto K, Maru-yama I, et al. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis (ISTH) and of the Japanese Ministry of Health and Welfare for overt DIC. Am J Hematol. 2003;74:17–22.CrossRefGoogle Scholar
  10. 10.
    Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31–41.CrossRefGoogle Scholar
  11. 11.
    Vincent J-L, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, et al. A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013;41:2070–9.CrossRefGoogle Scholar
  12. 12.
    Nishiyama T, Matsukawa T, Hanaoka K. Is protease inhibitor a choice for the treatment of pre- or mild disseminated intravascular coagulation? Crit Care Med. 2000;28:1419–22.CrossRefGoogle Scholar
  13. 13.
    Athale UH, Chan AKC. Thrombosis in children with acute lymphoblastic leukemia Part III. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of host environment. Thromb Res. 2003;111:321–7.CrossRefGoogle Scholar
  14. 14.
    Ishiguro A, Ezinne CC, Michihata N, Nakadate H, Manabe A, Taki M, et al. Pediatric thromboembolism: a nationwide survey in Japan. Int J Hematol. 2017;105:52–8.CrossRefGoogle Scholar
  15. 15.
    Couturier MA, Huguet F, Chevallier P, Suarez F, Thomas X, Escoffre-Barbe M, et al. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: the GRAALL experience. Am J Hematol. 2015;90:986–91.CrossRefGoogle Scholar
  16. 16.
    Beinart G, Damon L. Thrombosis associated with l-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia. Am J Hematol. 2004;77:331–5.CrossRefGoogle Scholar
  17. 17.
    Osone S, Moriguchi N, Imai T, Shinoda K, Ito T, Okada K, et al. l-Asparaginase-induced thrombosis: JACLS Retrospective Questionnaire Survey. Jpn J Pediatr Hematol Oncol. 2015;52:127–32 (article in Japanese).Google Scholar
  18. 18.
    Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac A-L, Drach J, et al. d-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009;27:4124–9.CrossRefGoogle Scholar
  19. 19.
    Rank CU, Toft N, Tuckuviene R, Grell K, Nielsen OJ, Frandsen TL, et al. Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients 1–45 years. Blood. 2018;131:2475–84.CrossRefGoogle Scholar
  20. 20.
    Ogawa C, Manabe A, Ohara A, Ishiguro A. Current national and international status of supportive therapy for the coagulopathy associated with L-asparaginase containing regimen for acute lymphoblastic leukemia. Jpn J Clin Hematol. 2013;54:316–8 (article in Japanese).Google Scholar
  21. 21.
    Zaunschirm A, Muntean W. Correction of hemostatic imbalances induced by l-asparaginase therapy in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1986;3:19–25.CrossRefGoogle Scholar
  22. 22.
    Gugliotta L, D’Angelo A, Belmonte MM, Viganò-D’Angelo S, Colombo G, Gatani L, et al. Hypercoagulability during l-asparaginase treatment: the effect of antithrombin III supplementation in vivo. Br J Haematol. 1990;74:465–70.CrossRefGoogle Scholar
  23. 23.
    Mitchell L, Andrew M, Hanna K, Abshire T, Halton J, Wu J, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Thromb Haemost. 2003;90:235–44.CrossRefGoogle Scholar
  24. 24.
    Hunault-Berger M, Chevallier P, Delain M, Bulabois CE, Bologna S, Bernard M, et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with l-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica. 2008;93:1488–94.CrossRefGoogle Scholar
  25. 25.
    Farrell K, Fyfe A, Allan J, Tait RC, Leach M. An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events. Leuk Lymphoma. 2016;57:2568–74.CrossRefGoogle Scholar
  26. 26.
    Grace RF, Dahlberg SE, Neuburg D, Sallan SE, Connors JM, Neufeld EJ, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152:452–9.CrossRefGoogle Scholar
  27. 27.
    Hough R, Rowntree C, Goulden N, Mitchell C, Moorman A, Wade R, et al. Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003. Br J Haematol. 2016;172:439–51.CrossRefGoogle Scholar
  28. 28.
    Greiner J, Schrappe M, Claviez A, Zimmermann M, Niemeyer C, Kolb R, et al. THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica. 2019;104:756–65.CrossRefGoogle Scholar
  29. 29.
    Abbott LS, Deevska M, Fernandez CV, Dix D, Price VE, Wang H, et al. The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase. Blood. 2009;114:5146–51.CrossRefGoogle Scholar
  30. 30.
    Steiner M, Attarbaschi A, Haas OA, Kastner U, Gadner H, Mann G. Fresh frozen plasma contains free asparagine and may replace the plasma asparagine pool during l-asparaginase therapy. Leukemia. 2008;22:1290.CrossRefGoogle Scholar
  31. 31.
    Meister B, Kropshofer G, Klein-Franke A, Strasak AM, Hager J, Streif W. Comparison of low-molecular weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50:298–303.CrossRefGoogle Scholar
  32. 32.
    Mitchell L, Lambers M, Flege S, Kenet G, Li-Thiao-Te V, Holzhauer S, et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood. 2010;115:4999–5004.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  1. 1.Department of Pediatrics, Graduate School of Medical ScienceKyoto Prefectural University of MedicineKyotoJapan
  2. 2.Department of PediatricsDokkyo Medical University School of MedicineTochigiJapan
  3. 3.Department of PediatricsAkita University HospitalAkitaJapan
  4. 4.Pediatric Hematology and Oncology DepartmentOkinawa Prefectural Medical Center and Children’s Medical CenterOkinawaJapan
  5. 5.Department of PediatricsSapporo Hokuyu HospitalHokkaidoJapan
  6. 6.Department of PediatricsJikei University School of MedicineTokyoJapan
  7. 7.Department of PediatricsKagoshima City HospitalKagoshimaJapan
  8. 8.Department of PediatricsGifu Municipal HospitalGifuJapan
  9. 9.Akabane Zaitaku ClinicTokyoJapan
  10. 10.Human Health Sciences, Graduate School of MedicineKyoto UniversityKyotoJapan

Personalised recommendations